AI-augmented longevity startup Everlab has raised $15 million (US$10m) for its preventative care platform.
The round was led by New York and London-based VC Left Lane Capital, with support from existing investor AfterWork Ventures.
The cash will be used on international expansion, further development of the platform, and integrated products.
Everlab previously raised $3 million in a pre-Seed round in December 2023 before launching publicly the following month. It was backed by Ten13, AfterWork, Flying Fox and the founders of Go1, and Aconex, and Temedica.
Founder and CEO Marc Hermann previously cofounded Foodspring, which was acquired by Mars in 2019.
The Melbourne startup uses a range of high-tech diagnostics, automation, and analysis to ward off potential chronic diseases and extend lifespan, offering a series of subscription tiers, appealing to health-conscious people drawn to the thinking of longevity-obsessed US tech entrepreneur Bryan Johnson, who’s turned his anti-aging obsession into a moneyspinner with “Project Blueprint“.
The cost of memberships range between $3000 and $1200 annually.
The Everlab regimen includes blood testing, whole-body MRIs, DEXA scans, VO2 max, ECG, isometric strength, continuous glucose monitoring, food journal analysis, and CT coronary angiograms. Added to that mix is online doctor consultations and personalised prevention plans.
Hermann said tens of thousands of customers are on its waitlist and Everlab is on track for 20x growth this year.
“By combining AI with the knowledge of leading clinicians, we’ve built a new kind of health platform designed to deliver smarter, earlier care to millions,” he said.
Hermann said Everlab has processed over 1,000,000 biomarkers through full-body health testing, with a quarter of test results returning abnormal results. Testing for around 2.5% of members revealed uncovering serious conditions such as blocked arteries, gastrointestinal tumours, early-stage cancers, and congenital brain abnormalities.
Left Lane Capital principal Laura Sillman said preventive care has always been a medical ideal but rarely a commercial reality.
“Everlab has built a product and model that makes it scalable, combining clinical depth with software leverage and operational precision.,” she said.
“We’re excited to support them as they build a category-defining platform.”
Daily startup news and insights, delivered to your inbox.